The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
The first human glucagon-like peptide-1 analog (liraglutide) was registered in Russia in May 2010. This review contains data on the results of randomizedclinical studies of this preparation applied to the treatment of patients with DM2 as monotherapy and in combination with traditional hypoglycemica...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN RU |
| Publicado: |
Endocrinology Research Centre
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e55f297af3a34572a8a0d9d97b6af3d0 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e55f297af3a34572a8a0d9d97b6af3d0 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e55f297af3a34572a8a0d9d97b6af3d02021-11-14T09:00:15ZThe role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus2072-03512072-037810.14341/2072-0351-5497https://doaj.org/article/e55f297af3a34572a8a0d9d97b6af3d02010-09-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5497https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378The first human glucagon-like peptide-1 analog (liraglutide) was registered in Russia in May 2010. This review contains data on the results of randomizedclinical studies of this preparation applied to the treatment of patients with DM2 as monotherapy and in combination with traditional hypoglycemicagents (LEAD 1-6 program). Liraglutide is shown to have advantages when used by patients with an excess body mass and obesity, those atrisk of cardiovascular diseases and prone to develop hypoglycemia. Patients treated with liraglutide (1.8 mg) more frequently achieved the desired efficacyendpoints (НbА1с < 7%, reduced body mass and AP control) of than those using traditional therapy (24 vs 3-14%).Marina Vladimirovna ShestakovaEndocrinology Research Centrearticleincretinshuman glucagon-like peptide-1 (glp-1)liraglutidevictozaNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 13, Iss 3, Pp 106-109 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN RU |
| topic |
incretins human glucagon-like peptide-1 (glp-1) liraglutide victoza Nutritional diseases. Deficiency diseases RC620-627 |
| spellingShingle |
incretins human glucagon-like peptide-1 (glp-1) liraglutide victoza Nutritional diseases. Deficiency diseases RC620-627 Marina Vladimirovna Shestakova The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus |
| description |
The first human glucagon-like peptide-1 analog (liraglutide) was registered in Russia in May 2010. This review contains data on the results of randomizedclinical studies of this preparation applied to the treatment of patients with DM2 as monotherapy and in combination with traditional hypoglycemicagents (LEAD 1-6 program). Liraglutide is shown to have advantages when used by patients with an excess body mass and obesity, those atrisk of cardiovascular diseases and prone to develop hypoglycemia. Patients treated with liraglutide (1.8 mg) more frequently achieved the desired efficacyendpoints (НbА1с < 7%, reduced body mass and AP control) of than those using traditional therapy (24 vs 3-14%). |
| format |
article |
| author |
Marina Vladimirovna Shestakova |
| author_facet |
Marina Vladimirovna Shestakova |
| author_sort |
Marina Vladimirovna Shestakova |
| title |
The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus |
| title_short |
The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus |
| title_full |
The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus |
| title_fullStr |
The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus |
| title_full_unstemmed |
The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus |
| title_sort |
role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus |
| publisher |
Endocrinology Research Centre |
| publishDate |
2010 |
| url |
https://doaj.org/article/e55f297af3a34572a8a0d9d97b6af3d0 |
| work_keys_str_mv |
AT marinavladimirovnashestakova theroleofhumanglucagonlikepeptide1analogintherapyoftype2dianetesmellitus AT marinavladimirovnashestakova roleofhumanglucagonlikepeptide1analogintherapyoftype2dianetesmellitus |
| _version_ |
1718429621040447488 |